Eli Lilly & Co. (NYSE: LLY) stock has unexpectedly meandered since the June 8, 2009 Buy recommendation at a price of $34.10, but the aforementioned probably represents selected investor jitters about the likely, federal health care reform legislation.

Ignore those jitters. The major components of health care reform have not been determined as of September 30, 2009, but the pharma calculation remains the same as it was in June. The legislation will be net-positive for major pharmaceutical companies, under the thesis that there will be 30-45 million more U.S. residents regularly - as opposed to sporadically - accessing health care services over the next decade, not including population growth.

Pharmaceutical company Eli Lilly & Co. (NYSE: LLY) is planning to cut 5,500 jobs over the next few years and reorganize into five business units. The company is looking to reduce costs and accelerate how long it takes new drugs to get to market, especially as its top performers see their patents expire. This translates to a workforce reduction of close to 14% – to 35,000. This measure doesn't include new positions in emerging markets with high potential and Japan.

The company hopes to cut as much as possible through attrition and retirements – and it would not indicate how many other positions would have to be cut.

Eli Lilly's goal is to slash its annual cost by $1 billion during this restructuring. The new business units will be: cancer, diabetes, established markets, emerging markets and Elanco, which is its animal health business. This is a change from the existing functional model, which separates U.S. and global marketing for each drug in the company's portfolio. Through the new structure, Lilly says, drug development and marketing will be tied more closely.

"While companies have been cutting dividends at an historic pace over the last 24 months, the fact is that there are still quality companies with long histories of paying dividends that represent good long-term investments," says Chuck Carlson, a specialist in companies offering dividend reinvestment plans.

In his top-notch The DRIP Investor he says, "The seven stocks featured here have each been paying a dividend for over 100 years, have raised their dividend annually for at least the last quarter century and offer direct-purchase plans.

DuPont (NYSE: DD) closed at $32.57. August 11 DD options were active on volume of 349,770 contracts into today's ex-dividend. DD August option implied volatility of 33; September is at 35; below its 26-week average 43 according to Track Data, suggesting decreasing price movement.

Eli Lilly (NYSE: LLY) closed at $33.18. LLY goes ex dividend today with a 49 cents dividend. On August 11 LLY options were active on volume of 28,953 contracts. LLY August option implied volatility is at 28, September is at 27; below its 26-week average of 31, suggesting decreasing price movement.

Options Update: Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Analyst upgrades:

• Deutsche Bank upgraded HealthSouth (NYSE: HLS) and Rehabcare (NYSE: RHB) to Buy from Hold after raising its Post Acute Care sector view to Positive from Neutral. The firm believes volumes and margin leverage can drive better than expected Q2 results and 2009 guidance. The firm raised its target on HealthSouth shares to $16 from $12 and on Rehabcare to $28 from $19.
  
• Jefferies upgraded Moody's (NYSE: MCO) to Hold from Underperform to reflect stabilizing credit markets and its belief regulatory concerns are overstated. The firm raised its target on shares to $30 from $19.
  
• Keefe Bruyette upgraded Goldman Sachs (NYSE: GS) to Outperform from Market Perform as it finds the stock inexpensive following the better than expected results. The firm has a $195 target on shares.
• Vale (NASDAQ: VALE) was upgraded to Buy from Neutral at BofA/Merrill.
  
• CNOOC (NYSE: CEO) was upgraded to Overweight from Equal Weight at Morgan Stanley.
  
• International Game Tech (NYSE: IGT) was upgraded to Buy from Neutral at Janney Montgomery.
  

Analyst upgrades:

• JPMorgan upgraded Franklin Resources (NYSE: BEN) to Overweight from Underweight to reflect performance and sales improvements, as well as benefits from the weakening U.S. dollar. The firm has a $94 target on the stock.
• Oppenheimer upgraded FormFactor (NASDAQ: FORM) to Outperform from Perform after channel checks indicated orders are recovering. The firm raised its target on shares to $30 from $22.
• KeyBanc upgraded Oshkosh (NYSE: OSK) to Buy from Hold citing the company's MRAP-ATV contract win, which they view as a "game changer." The firm has a $30 target on the stock.
• Novellus (NASDAQ: NVLS) was upgraded to Neutral from Underperform at Credit Suisse.
• Ternium (NYSE: TX) was upgraded to Buy from Neutral at Goldman.
• Cathay General (NASDAQ: CATY) was upgraded to Buy from Neutral at B. Riley.

Every year I find myself asking the same question: What to get dad for Father's Day. Well, Kiplinger's offers not to get our dads the same old presents -- another tie, another power tool -- but stocks in companies he probably likes or uses their products. That's a great idea, I thought, and decided to counter with five of my own.

• Kiplinger's suggests: Diageo (NYSE: DEO), the seller of such brands as Johnnie Walker, Smirnoff, Guinness and José Cuervo. Diageo has held up better than most during the recession -- thanks to a balanced portfolio of products, with higher exposure to mid-price, mainstream brands and less exposure to ultra-premium brands. The shares look reasonably priced. At $56.01, Diageo trades at 15 times estimated June 2009 earnings of $3.82 a share. The stock yields 2.8%.

• Another to consider: Molson Coors (NYSE: TAP), the seller of such brands as Coors, Blue Moon, Pilsner and Rickard's. Beer, probably even more so than hard liquor is supposed to hold better during a recession given the cheaper price point. The company's recent quarterly profits more than doubled. The shares trade at 13 times forward earnings of $3.33 and yield 2.2%.

TheStreet.com's Jim Cramer says there'll be a time to buy health care. But wait until the smoke clears.

Please don't tell me we are back in the world of no institutional memory again. That all that happened is we dropped enough points to freak everyone out, get the bears out of hibernation and then it is onward and upward. Nothing would shock me, especially the vehemence with which everyone hated the market again Monday.

If you replay what happened, most of the issues stemmed from statements made by the same Europeans that have said no more stimulus is needed, the same Europeans who have been in denial the whole way publicly, but believe me they have been stimulating like mad because their banks are a much larger size relative to their gross domestic product than ours and are in many ways worse off.

TheStreet.com's Jim Cramer suggests watching certain staples for hints that the flight to riskier plays is losing steam.

Will the endless "beta" trade out of slow-moving, "safe" drugs and foods and into companies like Freeport-McMoRan (NYSE: FCX) (Cramer's Take) and Caterpillar (NYSE: CAT) (Cramer's Take) ever end?

I think it won't end here, that's for certain, unless your staples stock goes to a 5% yield and the economy's macro data show a further breakdown. If we get some retail sales that are awful and some employment numbers that show a further trashing, then we are going to see a momentary blip up in stocks like Pepsi (NYSE: PEP) (Cramer's Take) and Clorox (NYSE: CLX) (Cramer's Take), but perhaps no more than that.

Analyst upgrades:

• Argus upgraded CBRL Group (NASDAQ: CBRL) to Buy from Hold as it believes increased efficiency at Cracker Barrel will help to boost restaurant traffic and same-store sales. The firm has a $33 target on shares.
  
• Citigroup upgraded shares of Eli Lilly (NYSE: LLY) to Buy from Hold on expectations the company's blood-thinning drug Effient is on track for a Q2 U.S. launch. The firm raised its price target on shares to $41 from $36.
  
• Needham upgraded Intel (NASDAQ: INTC) to Buy from Hold after recent channel checks suggested Intel's PC OEM orders are tracking better than expected. The firm expects Intel to keep prices and product mix stable, enabling margins to recover in Q2. Needham has an $18 target on INTC shares.
• SEI Investments (NASDAQ: SEIC) was upgraded to Outperform from Market Perform at Keefe Bruyette.
  
• Consolidated Edison (NYSE: ED) was raised at Jefferies to Buy from Hold.
  
• Taleo (NASDAQ: TLEO) was lifted to Outperform from Perform at Oppenheimer.

Pharmaceutical giant Schering-Plough (NYSE: SGP) stepped into the earnings spotlight today, and it is reaping the rewards of a positive report. SGP posted fourth-quarter earnings of $480 million, or 27 cents per share; but adjusted earnings came in at $633 million, or 39 cents per share.

This beat fourth quarter results of a year ago, when the company lost $2.08 per. Today's announcement also handily trounced the Street's expectations of 30 cents per share for the quarter, per analysts' estimates.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Altria Group Inc. (NYSE: MO) Q4 profit rose on higher prices, and its forecast matched expectations.
• Amgen Inc. (NASDAQ: AMGN) Q4 earnings grew on cost cutting but revenue remained flat.
• Black & Decker Corp. (NYSE: BDK) shares tanked after the dismal Q4 report, and it announced job cuts.
• Carpenter Technology Corp. (NYSE: CRS) Q2 numbers resulted in a downgrade from one analyst.
• ConocoPhillips (NYSE: COP) reported a Q4 loss due to writedowns from recent acquisitions.
• DuPont (NYSE: DD) swung to a bigger-than-expected Q4 loss and its revenue fell as well.
• Eli Lilly & Co. (NYSE: LLY) swung to a Q4 loss on acquisition costs but reaffirmed its guidance.

Ford Motor Co. (NYSE: F) posted a loss of $5.9 billion, or $2.46 per share, in the fourth quarter, but it said that it still has no plans to seek federal aid unless economic conditions worsen. Ford burned through $5.5 billion in cash during the quarter. Excluding one-time items, Ford lost $1.37 per share, below estimates of a loss of $1.30 per share. Revenue fell to $29.2 billion, down from $45.5 billion for the fourth quarter of 2007. Ford's shares are gaining nearly 2.5% in premarket trading. Fifteen minutes after the open, Ford shares were 2.2% lower.

Starbucks (NASDAQ: SBUX) reported worse-than-expected quarterly results late Wednesday after the close, as its quarterly profit dropped 69%. It also also announced 6,700 more job cuts and plans to close 300 stores. As the company has been hurt by tighter consumer spending, it said it will not provide any sales or earnings guidance. SBUX shares are defclining over 4% in premarket trading. Fifteen minutes after the open, SBUX shares were flattish.

Lots of quarterly reports to come this week, and if you're one of those looking to earnings for signs of the direction of the markets or of the economy, well its going to be a rough week. Analysts surveyed by Thomson Reuters, by and large, expect earnings declines to be deeper and more numerous than earnings gains. And that's true across sectors: Caterpillar Inc. (NYSE: CAT), Amazon.com Inc. (NASDAQ: AMZN), U.S. Steel Corp. (NYSE: X), Wells Fargo & Co. (NYSE: WFC), New York Times Co. (NYSE: NYT), Starbucks Corp. (NASDAQ: SBUX), Boeing Co. (NYSE: BA), Starwood Hotels & Resorts Worldwide Inc. (NYSE: HOT), American Express Co. (NYSE: AXP), Altria Group Inc. (NYSE: MO), and Texas Instruments Inc. (NYSE: TXN) are all expected to post double-digit declines this week.

Even the petroleum industry is not immune, with Chevron Corp. (NYSE: CVX), Valero Energy Corp. (NYSE: VLO), ExxonMobil Corp. (NYSE: XOM), Murphy Oil Corp. (NYSE: MUR), ConocoPhillips (NYSE: COP), Occidental Petroleum Corp. (NYSE: OXY), and Hess Corp. (NYSE: HES) expected to report profits that were as much as 65.3% lower in the fourth quarter.

And analysts expect Freeport-McMoRan Copper & Gold Inc. (NYSE: FCX), Tyson Foods Inc. (NYSE: TSN), DuPont (NYSE: DD), and Sun Microsystems Inc. (NASDAQ: JAVA) to have swung to losses for the most recent quarter, from profits in the same period a year ago. And Ford Motor Co. (NYSE: F) is expect to have deepened its net loss.

But not all is doom and gloom. There are some anticipated EPS gainers as well. Here's a closer look at a few of them.

JPMoragn Chase (NYSE: JPM) has amazingly managed to surprise Wall Street when it reported its quarterly results this morning. Maybe that's why it decided to report six days early. JPMorgan even managed to avoid a loss in the fourth quarter, perhaps a sign it is managing much better than others during this crisis than other banks. Of course, it wasn't that rosy as its reported profit of $702 million, or 7 cents per share, was down sharply -- 76% -- from $2.97 billion, or 86 cents per share, a year ago. Analysts expected break-even results. Shares were 3% higher in premarket trading.

Apple Inc. (NASDAQ: AAPL) CEO Steve Jobs announced Wednesday after the close he is taking a medical leave of absence until the end of June. COO Tim Cook will be taking over Jobs' day-to-day operations, but Jobs said he'll still be involved in strategic decisions. When shares resumed trading in after-hours, they were down some 8%. Only last week Jobs said he suffers from a hormone imbalance that caused him to lose weight, but that he will remain CEO during his recovery. This has been quite the reversal that he says is due to his problems being "more complex" than originally thought.
This morning, also, Bloomberg reports that Jobs "could be facing surgery to remove his pancreas," according to doctors.
Apart from Jobs illness, though, Gartner has released a preliminary report on U.S. and worldwide PC shipment, which places Apple in fourth place in U.S market share at 8.0% in the fourth quarter, down from 9.5% in the third quarter of 2008.
RBC Capital Mkts downgraded AAPL from Sector Perfrom to Underperform. Oppenheimer lowered its target price from $135 to $120.
AAPL shares were down 7% in premarket trading.